Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316584 | 0.83 | GAA (0.42) | TSHRGAAHSD17B10MGAMSI | |
| SCHEMBL7682664 | 0.81 | ALDH1A1 (0.38) | HSD17B10MAPK1 | |
| SCHEMBL10719396 | 0.80 | TSHR (0.42) | TSHRGAAHSD17B10MGAMSI | |
| SCHEMBL5547017 | 0.79 | DGAT1 (0.36) | GAAHSD17B10CA12CA14CA2 | |
| SCHEMBL19821812 | 0.78 | TSHR (0.40) | TSHRGAAHSD17B10MGAMSI | |
| SCHEMBL6384724 | 0.77 | MAPK1 (0.32) | HSD17B10MAPK1 | |
| SCHEMBL5503088 | 0.77 | USP2 (0.34) | TSHRHSD17B10MAPK1 | |
| SCHEMBL13330530 | 0.77 | TSHR (0.39) | TSHRGAAHSD17B10MGAMSI | |
| SCHEMBL2075717 | 0.75 | TSHR (0.55) | TSHRGAAHSD17B10MGAMSI | |
| SCHEMBL5607319 | 0.75 | GAA (0.50) | TSHRGAAHSD17B10MGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105492075-B | Inhibitors of viral replication, their preparation method and their therapeutical uses | HIVIH公司 | 2019-11-12 | — | — | CN | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| CN-108026113-A | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV保健英国第五有限公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| CN-107001357-A | Imidazo [1,2 a] pyridine derivate as human immunodeficiency virus replication inhibitor | VIIV保健英国第五有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-104583214-B | The inhibitor of human immunodeficiency virus replication | 百时美施贵宝公司 | 2017-06-09 | — | — | CN | disclosed |
| CN-105189510-B | Inhibitors of human immunodeficiency virus replication | 百时美施贵宝公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-106536513-A | Isoindolinone derivatives useful as antiviral agents | VIIV保健英国有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070203081-A1 | AMINOGLYCOSIDES AS ANTIBIOTICS | WAYNE STATE UNIVERSITY | 2007-08-30 | — | — | US | disclosed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-7220727-B2 | For therapy of bacterial infection in a mammal | WAYNE STATE UNIVERSITY (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | TSHR 4297/4885GAA 1675/4885HSD17B10 4007/4885 |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | TSHR 396/4885GAA 1584/4885HSD17B10 508/4885 |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | AHR, HCAR2, HCAR1 | TSHR 162/4885GAA 692/4885HSD17B10 964/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | TSHR 4297/4885GAA 1675/4885HSD17B10 4007/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | TSHR 4297/4885GAA 1675/4885HSD17B10 4007/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | TSHR 504/4885GAA 1660/4885HSD17B10 417/4885 |
| US-20070203081-A1 | AMINOGLYCOSIDES AS ANTIBIOTICS | PIGS, ALG8, NPEPPS | TSHR 4032/4885GAA 9/4885HSD17B10 2795/4885 |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | ALDH1A2, ALDH1A3, GRHPR | TSHR 2253/4885GAA 788/4885HSD17B10 91/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | TSHR 396/4885GAA 1584/4885HSD17B10 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.